Results 141 to 150 of about 14,494 (232)

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source

Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives

Life
Body weight is impacted by several individual host and environmental factors. In a person living with HIV (PLWH), weight is also influenced by the disease stage.
Konstantinos Markakis, Olga Tsachouridou, Eleni Georgianou, Dimitrios Pilalas, Sideris Nanoudis, Symeon Metallidis   +5 more
doaj   +1 more source

Tenofovir alafenamide/tenofovir disoproxil fumarate

Reactions Weekly, 2021
openaire   +1 more source

Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort

International Journal of Infectious Diseases
Objectives: Long-term effects of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on hepatic, renal, and metabolic parameters remain poorly characterized, especially in people with HIV (PWH) and hepatitis B virus ...
Mariacristina Poliseno, Sergio Lo Caputo, Alessandro Tavelli, Roberta Gagliardini, Lidia Gazzola, Annalisa Saracino, Teresa Antonia Santantonio, Nicola Squillace, Massimo Puoti, Valentina Mazzotta, Adndrea Antinori, Antonella d’Arminio Monforte, Alessandro Cozzi-Lepri   +12 more
doaj   +1 more source

Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort

JHEP Reports
Background & Aims: The optimal antiviral agent for patients with chronic hepatitis B (CHB) at risk for osteoporosis remains debated. The aim of this study was to compare the incidence of osteoporosis and osteoporotic fractures between patients ...
Yoon E. Shin, Jae Young Kim, Hyuk Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim   +5 more
doaj   +1 more source

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

JGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka   +10 more
doaj   +1 more source

The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections

Viruses
Rilpivirine (RPV, R278474) was highlighted in 2005, two years after the death of Dr. Paul Janssen, as the ideal non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV infections.
Erik De Clercq
doaj   +1 more source

Emtricitabine/Tenofovir Alafenamide Fumarate [PDF]

, 2020
openaire   +1 more source

Highlights from the 9th IAS conference on HIV science, 23-26 July 2017, Paris, France [PDF]

, 2017
The 9th International AIDS Society Conference on HIV Science (IAS 2017) took place at the Palais des Congrès, in Paris, France, from 23 to 26 July 2017, chaired by Linda-Gail Bekker and Jean-François Delfraissy. It was organised by the International AIDS
Barber, Tristan J, Kinloch-de Loës, Sabine, Psomas, Christina K, Rutsaert, Sofie   +3 more
core   +2 more sources